Outcomes in Femoropopliteal Disease Stratified by Translesional Pressure Gradient



Status:Completed
Conditions:Peripheral Vascular Disease, Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - Any
Updated:9/14/2018
Start Date:February 6, 2015
End Date:July 13, 2016

Use our guide to learn which trials are right for you!

1. To perform an observational analysis to determine if mean translesional gradient
measurements (TLG) are associated with differences in clinical outcomes in patients with
femoropopliteal arterial disease and claudication.

2. Hypothesis: Patients stratified by a residual translesional gradient peripheral revascularization or angiography alone will have better clinical outcomes
than patients with TLG > 11 mmHg as assessed by six minute walk (6MW), walking
impairment questionnaire scores (WIQ), ankle brachial index and need for repeat
procedure at 6 months.

The role of measuring translesional pressure gradients(TLG) in peripheral arterial disease
lesions below the iliac artery is unclear. In a previous study the investigators demonstrated
that a pressure wire can be effectively used to measure gradients in the femoropopliteal (FP)
arterial bed showing good correlation between TLGs recorded with exercise ankle brachial
index and walking impairment scores. However there is a no evidence that effectively
modifying the gradient or having a high residual gradient after revascularization or just
with medical therapy correlates with worse clinical outcomes.

This is a prospective, single center, observational clinical study to evaluate whether
measurement of mean residual TLG at the time of angiography and/or immediately after
endovascular revascularization are associated with clinically important outcomes in patients
with claudication symptoms.

Prior to angiography they will be asked to complete an ankle brachial index evaluation,
baseline six minute walk test and walking impairment questionnaire. Arterial access should be
obtained in the contralateral common femoral artery to the symptomatic limb if feasible.
Angiographic images are to be obtained, interpreted and clinical decisions regarding
endovascular treatment are to be made per treating physician's discretion prior to obtaining
translesional pressure gradients. In patients whose angiogram does not meet exclusion
criteria and do not have a chronic total occlusion (CTO) a baseline TLG will be obtained. A
0.014" pressure wire/catheter to measure pressure will be inserted. After baseline
calibration in the superficial femoral artery, the wire will be inserted past the narrowest
lesion into the popliteal vessel. Intra-arterial adenosine 100-200 mcg will be given for
hyperemia and measurements are to be recorded. If an intervention is planned, repeat
measurements are to be obtained at the end of the procedure. If no intervention is planned
this will be the residual or final TLG recorded. If baseline measurement are unable to
obtained due to a CTO then only a post intervention residual TLG will be obtained and
included in analysis. The operator will be blinded to the pre and post TLG measurements by
turning the display monitor away from the procedure table and towards the recorder situated
in the procedure room when measurements are being obtained.

Patients will follow up within two weeks post angiography for routine scheduled follow up and
will obtain repeat ABI, WIQ, and six minute walk if they underwent revascularization.
Treating physicians and study coordinators collecting these test measurements will be blinded
to TLG measurements but not to angiography and treatment. Patients will again be evaluated at
6 months follow up with repeat ABI, WIQ and six minute walk.

Inclusion Criteria:

- Signed informed consent

- At least 18 years old

- Unilateral lower limb claudication Rutherford class 2-4

- Subjects must be able to complete screening six minute walk, walking impairment
questionnaire, and baseline ankle brachial index

- Estimated survival ≥1 year in the judgment of the primary operator

- Documented symptomatic femoropopliteal (FP) atherosclerotic disease with at least
moderate angiographic stenosis in the symptomatic lower extremity

- Subjects with multilevel disease can be screened and enrolled after treatment of other
non FP PAD

Exclusion Criteria:

- Life expectancy less than 12 months or other medical co-morbid condition(s) that could
limit the subject's ability to participate in the trial, limit the subject's
compliance with the follow-up requirements, or impact the scientific integrity of the
trial

- Severe Bilateral claudication

- Known hypersensitivity or contraindication to contrast dye that, in the opinion of the
investigator, cannot be adequately pre-medicated

- Known hypersensitivity to adenosine or moderate to severe asthma

- Pregnancy

- Serum Creatinine >2.5

- Vascular graft, aneurysm or postsurgical stenosis of the target vessel

- Documented untreated severe iliac or below-the knee stenosis with < 2 vessel run-off
in leg with femoropopliteal stenosis or untreated bilateral symptomatic peripheral
arterial disease
We found this trial at
1
site
Dallas, Texas 75216
?
mi
from
Dallas, TX
Click here to add this to my saved trials